ALPROLIX^®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE^1–3

IMPROVED BLEED PROTECTION AND REDUCED TREATMENT BURDEN
vs prior SHL FIX¹¹

A real-world study across the UK, Denmark and Germany up to 24 months investigated
patients switching from SHL FIX* to ALPROLIX prophylaxis (N=30), reported:¹¹

Reduced ABR¹¹

ABR improved numerically with ALPROLIX vs pre-switch FIX¹¹

Pre- vs post-switch mean ABR (N=30)¹¹

Reduced injection frequency¹¹

One less injection per week after switching (n=24)¹¹

Before switch: 2.0 injections/week
After switch: 1.0 injection/week

p-values not reported

Reduced factor consumption¹¹

Average factor consumption numerically reduced by 27.7 IU/kg/week
post-switch to ALPROLIX from SHL FIX prophylaxis¹¹

Pre- and post-switch mean weekly factor consumption (n=24)¹¹

*On-demand and prophylaxis.^{11 †}Mean change between pre- and post-switch factor consumption.¹¹
ABR, annualised bleeding rate; FIX, factor IX; IU, international unit; IQR, interquartile range; SD, standard deviation; SHL, standard half-life.

FIX, factor IX; SHL, standard half-life.

Retrospective, multicentre, chart review evaluating adult and paediatric medical records¹¹

Data obtained from centres in Denmark (n=9), Germany (n=9) and the UK (n=12)¹¹

FIX, factor IX; SHL, standard half-life.

No safety data were collected.